Ieq Capital LLC Grows Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Ieq Capital LLC grew its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 465.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 26,993 shares of the medical research company’s stock after buying an additional 22,222 shares during the period. Ieq Capital LLC’s holdings in Exact Sciences were worth $1,517,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Huntington National Bank lifted its holdings in shares of Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after acquiring an additional 352 shares during the last quarter. RPg Family Wealth Advisory LLC bought a new stake in Exact Sciences in the third quarter worth about $34,000. Capital Performance Advisors LLP purchased a new position in shares of Exact Sciences during the third quarter valued at approximately $35,000. Asset Planning Inc bought a new position in shares of Exact Sciences during the fourth quarter valued at approximately $40,000. Finally, Modus Advisors LLC bought a new position in shares of Exact Sciences during the fourth quarter valued at approximately $43,000. 88.82% of the stock is currently owned by institutional investors.

Exact Sciences Trading Up 4.1 %

Shares of NASDAQ EXAS opened at $51.28 on Tuesday. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62. The business has a fifty day moving average price of $54.72 and a 200 day moving average price of $60.00. The stock has a market capitalization of $9.53 billion, a P/E ratio of -9.21 and a beta of 1.24. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The business had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. Equities research analysts expect that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on EXAS shares. Benchmark restated a “buy” rating and set a $65.00 price objective on shares of Exact Sciences in a report on Monday, January 13th. Citigroup cut their price target on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. TD Cowen lifted their price objective on shares of Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Stifel Nicolaus dropped their target price on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, Sanford C. Bernstein lifted their price target on shares of Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $72.24.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.